Shell Asset Management CO Innoviva, Inc. Transaction History

Shell Asset Management CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$11.39 - $13.72 $101,302 - $122,025	-8,894 Reduced 44.56%	11,064 $141,000
Q1 2023 May 15, 2023	SELL	$10.73 - $13.6 $751 - $952	-70 Reduced 0.35%	19,958 $225,000
Q4 2022 Feb 07, 2023	SELL	$11.8 - $13.78 $47,943 - $55,988	-4,063 Reduced 16.87%	20,028 $265,000
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $73,293 - $96,083	-6,313 Reduced 20.76%	24,091 $280,000
Q2 2022 Aug 09, 2022	BUY	$14.32 - $19.88 $773 - $1,073	54 Added 0.18%	30,404 $449,000
Q1 2022 May 04, 2022	SELL	$15.39 - $20.25 $69,101 - $90,922	-4,490 Reduced 12.89%	30,350 $587,000
Q4 2021 Feb 09, 2022	BUY	$15.91 - $18.72 $2,625 - $3,088	165 Added 0.48%	34,840 $601,000
Q3 2021 Nov 04, 2021	SELL	$13.06 - $17.24 $19,459 - $25,687	-1,490 Reduced 4.12%	34,675 $579,000
Q2 2021 Aug 12, 2021	BUY	$11.45 - $13.96 $164,067 - $200,032	14,329 Added 65.62%	36,165 $485,000
Q2 2020 Aug 10, 2020	BUY	$11.49 - $15.26 $250,895 - $333,217	21,836 New	21,836 $305,000

228

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.21B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.